Header links
Intranet
Donate now
image/svg+xml Map
Contact us

30/09/2026

Vall d'Hebron Talks by VHIR 'Exercise and Anticancer Immunity'
Ubicació
Boardroom of the VHIR Edifici Central (Floor 0)
Etiqueta
Vall d'Hebron Talks by VHIR
05/10/2026

Vall d'Hebron Talks by VHIR 'CRISPR Universe: where are today? From scissors to bridges'
Ubicació
Aula 114 del Mòdul Sud de la Unitat Docent de Vall d'Hebron
Etiqueta
Vall d'Hebron Talks by VHIR

Catalogue of procedures based on the 3Rs

14/09/2026

Vall d'Hebron Talks by VHIR 'Revisiting the old paradigms in Sepsis: from "phases" to "patients"

Ubicació
Sala d'actes de l'Edifici Central del VHIR (Planta 0)
Etiqueta
Vall d'Hebron Talks by VHIR
02/10/2026

Jornada Científica II. 'Respirant innovació: Connectivitat, personalització i equitat en Pneumologia'
Ubicació
Sala d'actes de l'Edifici Central del VHIR (Planta 0)
Etiqueta
Jornades

Ensayo doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad del tratamiento con nerandomilast oral en pacientes con esclerosis sistémica.

Contact
  • Protocol code: 1305-0052 (VERANDA™-SSc)
  • EudraCT code: No aplica
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Guillen Del Castillo, Alfredo
  • Research group:  Malalties sistèmiques
  • Service: Medicina Interna
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase III, multicéntrico y de un solo brazo para evaluar la eficacia,farmacocinética, seguridad y tolerabilidad de atrasentán en pacientes pediátricos de 2a 18 años con nefropatía primaria por inmunoglobulina A

Contact
  • Protocol code: CEXV811B12301
  • EudraCT code: No aplica
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Ariceta Iraola, Gema
  • Research group:  Fisiopatologia renal
  • Service: Nefrologia Pediàtrica
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Ensayo en canasta determinante, en fase III, multicéntrico, internacional, aleatorizado, sinenmascaramiento, de grupos paralelos y con comparador activo, en el que se investigan la eficacia y laseguridad de la lonapegsomatropina administrada una vez por semana en comparación con la somatropinadiaria en niños y adolescentes prepúberes con retraso del crecimiento o talla baja debido a trastornos consuficiente hormona del crecimiento: síndrome de Turner, deficiencia del SHOX, talla pequeña para la edadgestacional y talla baja idiopática

Contact
  • Protocol code: ASND0047
  • EudraCT code: No aplica
  • Pathology: Tumors
  • Principal investigator:  Clemente Leon, Maria
  • Research group:  Creixement i desenvolupament
  • Service: Pediatria General i Especialitats
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase 3, aleatorizado, multicéntrico, de grupos paralelos, de no inferioridad, abierto que evalúa la eficacia, seguridad y tolerabilidad de cabotegravir de acción ultra prolongada junto con rilpivirina de acción ultra prolongada o cabotegravir de acción prolongada junto con rilpivirina de acción prolongada en adultos y adolescentes con VIH que están virológicamente suprimidos con tratamiento antirretroviral oral

Contact
  • Protocol code: 222794
  • EudraCT code: No aplica
  • Pathology: Malalties del sistema respiratori
  • Principal investigator:  Burgos Cibrian, Joaquin
  • Research group:  Malalties infeccioses
  • Service: Infeccioses
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase 3 aleatorizado, doble ciego y controlado conplacebo para evaluar la eficacia, la seguridad y la tolerabilidad de votoplam enparticipantes con enfermedad de Huntington.

Contact
  • Protocol code: CHTT227A12301
  • EudraCT code: No aplica
  • Pathology: Malalties del sistema nerviós
  • Principal investigator:  Hernández Vara, Jorge
  • Research group:  Malalties neurodegeneratives
  • Service: Neurologia
  • Phase: Fase II
  • Recruiting: Closed
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.
Subscribe to